Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
SGLT2 inhibitors benefit heart and kidney health in both diabetic and non-diabetic people, working through mechanisms beyond just lowering blood sugar.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were developed as glucose-lowering agents but have emerged as cardiorenal therapies in people with and without diabetes. The reported conclusion is: This integrated model may better explain why clinical benefits extend beyond glucose lowering and are observed across populations, including individuals without diabetes.
What the study was
- Study design
- Journal article; design not clearly reported in abstract
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Handbook of experimental pharmacology
Why it surfaced
Retained for Cardiovascular-metabolic; score reflects the available PubMed abstract, study design, clinical relevance, and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.